# Clinical Genomics Evidence & Deep Research Synthesis: Melinda Ehrle
**Patient / Cohort Identifier:** `Melinda_Ehrle` | **Report Date:** October 13, 2026
**Target Audience:** Medical Geneticist · Subspecialty Investigator · Primary Care Physician · Clinical Bioinformatician
**Sequencing Depth & Reference:** BAM Aligned Mean Depth **33.4x** on GRCh38.p14

### Orientation: What We Are Covering
This clinical genomics research dossier evaluates **1653 prioritized variants across 1129 clinical genes** and **41 pharmacogenes (377 screened medications)** for **Melinda Ehrle** (`Melinda_Ehrle`), backed by **33.4x** BAM mean sequencing depth. This synthesis separates **Mechanistic Causality** (coding loss-of-function, canonical splice disruption, 3D active-site destabilization) from **Statistical Correlation** (GWAS linkage disequilibrium proxies and common polygenic modifiers), audits **Intra-Gene Cis/Trans Phasing** across multi-variant genes, and provides a **Biomarker Ground-Truthing & Longitudinal Futures Roadmap**.

### Body

#### 1. Primary Mechanistic & High-Priority Clinical Findings (With Locus Depth, VAF & Confidence)
| Gene | Variant & Coordinate (GRCh38) | Zygosity & Phase | Locus DP & VAF | ClinVar Status | CADD (Phred) / REVEL | AlphaGenome AVI (Phred) & Top Driver | Confidence |
| :--- | :--- | :--- | :---: | :--- | :--- | :--- | :---: |
| **POLG** | `p.Gly737Arg` (`chr15:89323460`) | Heterozygous (Paternal) | `31x` / `0.61` | **Pathogenic/Likely pathogenic** | 26.3 / 0.94 | 30.3 (AlphaMissense) | **0.95** |
| **TAT** | `p.Arg57Ter` (`chr16:71576247`) | Heterozygous (Maternal) | `52x` / `0.46` | **Pathogenic** | 36.0 / — | 38.8 (Protein Termination) | **0.95** |
| **ATM** | `c.1236-2del` (`chr11:108250699`) | Heterozygous (Unknown) | `18x` / `0.17` | **Pathogenic/Likely pathogenic** | — / — | — | **0.71** |
| **VDR** | `c.-1172A>G` (`chr12:47906043`) | Heterozygous (Unphased) | `21x` / `0.19` | **Likely pathogenic** | 5.4 / — | 2.1 (DNASE-seq) | **0.68** |
| **MC1R** | `p.Asp294His` (`chr16:89920138`) | Heterozygous (Paternal) | `25x` / `0.52` | **Conflicting classifications of pathogenicity|risk factor** | 26.9 / 0.61 | 24.5 (Cactus) | **0.82** |
| **AMPD1** | `p.Glu435Gly` (`chr1:114677435`) | Heterozygous (Unphased) | `41x` / `0.49` | **Uncertain significance** | 32.0 / 0.95 | 28.2 (AlphaMissense) | **0.88** |
| **CTH** | `p.Thr67Ile` (`chr1:70415987`) | Heterozygous (Unphased) | `39x` / `0.46` | **Conflicting classifications of pathogenicity** | 25.5 / 0.93 | 27.8 (AlphaMissense) | **0.88** |

#### 2. Mechanistic Causality vs. Statistical Correlation Matrix
To prevent clinical over-interpretation of statistical GWAS proxies, cohort findings are stratified across four epistemic tiers:

| Epistemic Class | Count in Cohort | Representative Genes | Mechanistic vs. Statistical Distinction & Clinical Rule |
| :--- | :---: | :--- | :--- |
| **Q1 · Confirmed Mechanistic Causality** | **5** | ATM, POLG, TAT, MC1R, CYP3A5 | **Direct Physical Disruption + Clinical Proof:** Concordant ClinVar P/LP curation backed by high AI functional impact (CADD ≥ 20 / AVI ≥ 20). Eligible for preventive clinical surveillance. |
| **Q2 · Cryptic AI-Predicted Disruptors** | **159** | HLA-DRB5, CEP63, GUSB, HLA-DRB1, IL17RC, TEK | **Biophysical Disruption Without Clinical Database Entry:** Severe deep-learning predicted splice, chromatin, or 3D folding impact currently VUS/unreviewed in ClinVar. Prioritize for biomarker ground-truthing. |
| **Q3 · Database-Curated / Statistical & PGx Modifiers** | **377** | CD40, HEPACAM, HLA-DRB1, TAT, VPS35L, VDR | **Curated Hypomorphic, PGx & Statistical GWAS Loci:** Includes enzymatic drug-response alleles and statistical population modifiers; must **never** trigger invasive monogenic workups. |
| **Q4 · Protective & Resilience Offsets** | **10** | ADH1C, GNPTAB, TLR1, CASP8, EDNRA, FCGR2B | **Risk-Attenuating & Cardioprotective Alleles:** Curated protective modifiers buffering baseline metabolic or vascular pathway susceptibility. |

##### 2.1 High-Priority Cryptic AI Disruptors (AlphaGenome 18-Modality Attribution)
| Gene | Variant & Coordinate | Zygosity & Phase | AVI (Phred) & Percentile | Primary Modality Driver | Top SHAP Attribution Weights (`fi_*`) |
| :--- | :--- | :--- | :---: | :--- | :--- |
| **VWA3B** | `p.Glu372Ter` (`chr2:98162976`) | Heterozygous (Unphased) | **50.8** (Top 0.00%) | **Protein Termination** | Protein Term: 52.0%, Splicing: 18.9%, Cactus 241-Way: 10.2% |
| **CEP63** | `p.Gln185His` (`chr3:134537268`) | Heterozygous (Maternal) | **38.6** (Top 0.01%) | **Splicing** | Splicing: 40.3%, Cactus 241-Way: 23.1%, AlphaMissense: 19.6% |
| **OGFOD3** | `c.380+1G>A` (`chr17:82411454`) | Heterozygous (Unphased) | **33.8** (Top 0.04%) | **Splicing** | Splicing: 53.6%, Cactus 241-Way: 27.2%, PhastCons 470-Way: 8.6% |
| **NIPSNAP2** | `c.712+1G>T` (`chr7:55994989`) | Heterozygous (Unphased) | **33.8** (Top 0.04%) | **Splicing** | Splicing: 58.6%, Cactus 241-Way: 27.4%, PhastCons 470-Way: 9.4% |
| **HLA-DRB5** | `c.101-1G>A` (`chr6:32522175`) | Heterozygous (Unphased) | **28.0** (Top 0.16%) | **Splicing** | Splicing: 76.6%, PhastCons 470-Way: 12.7%, Cactus 241-Way: 4.5% |
| **AMPD1** | `p.Glu435Gly` (`chr1:114677435`) | Heterozygous (Unphased) | **28.2** (Top 0.15%) | **AlphaMissense** | AlphaMissense: 51.3%, Cactus 241-Way: 25.4%, PhastCons 470-Way: 14.7% |

#### 3. Intra-Gene Cis / Trans Phase Auditor & Cross-Pathway Epistasis
Parental and read-backed phasing across all multi-variant genes in **Melinda Ehrle** resolved **3 Trans Multi-Variant Genes** (variants on opposite parental homologs; 0 confirmed biallelic pathogenic recessive compound-heterozygotes) and **7 Cis Haplotype Genes** (variants co-inherited on the same parental chromosome, leaving the opposite parental homolog completely wild-type).

| Gene | Organ System | Phased Architecture | Variant Count (Mat / Pat) | Max CADD (Phred) | Clinical & Inheritance Interpretation |
| :--- | :--- | :--- | :---: | :---: | :--- |
| **DNAH11** | Heart & Cardiovascular | **TRANS (Biallelic / Compound Het Candidate)** | 4 (1M / 1P) | 21.8 | 1 Maternal + 1 Paternal alleles in trans across DNAH11 |
| **ABCB1** | Multisystem | **TRANS (Biallelic / Compound Het Candidate)** | 17 (1M / 7P) | 7.0 | 1 Maternal + 7 Paternal alleles in trans across ABCB1 |
| **UGT2B7** | Multisystem | **TRANS (Biallelic / Compound Het Candidate)** | 14 (1M / 1P) | 6.7 | 1 Maternal + 1 Paternal alleles in trans across UGT2B7 |
| **TMEM43** | Heart & Cardiovascular | **CIS (Paternal Co-Inherited Haplotype)** | 2 (0M / 2P) | 32.0 | 2 variants co-inherited in cis on Paternal chromosome (WT Maternal copy intact) |
| **PTPRC** | Multisystem | **CIS (Maternal Co-Inherited Haplotype)** | 3 (2M / 0P) | 22.8 | 2 variants co-inherited in cis on Maternal chromosome (WT Paternal copy intact) |
| **ATR** | Multisystem | **CIS (Paternal Co-Inherited Haplotype)** | 2 (0M / 2P) | 17.3 | 2 variants co-inherited in cis on Paternal chromosome (WT Maternal copy intact) |
| **PCSK9** | Heart & Cardiovascular | **CIS (Paternal Co-Inherited Haplotype)** | 8 (0M / 2P) | 14.3 | 2 variants co-inherited in cis on Paternal chromosome (WT Maternal copy intact) |
| **RYR1** | Heart & Cardiovascular | **CIS (Paternal Co-Inherited Haplotype)** | 15 (0M / 11P) | 10.4 | 11 variants co-inherited in cis on Paternal chromosome (WT Maternal copy intact) |
| **APOE** | Multisystem | **CIS (Maternal Co-Inherited Haplotype)** | 3 (2M / 0P) | 10.2 | 2 variants co-inherited in cis on Maternal chromosome (WT Paternal copy intact) |
| **ETNK2** | Multisystem | **CIS (Paternal Co-Inherited Haplotype)** | 3 (0M / 2P) | 1.6 | 2 variants co-inherited in cis on Paternal chromosome (WT Maternal copy intact) |

#### 4. Actionable Pharmacogenomic (CPIC / DPWG) Medication Matrix
| Prescribing Action | Screened Drug Count | Key Affected Medications & Causal Pharmacogenes |
| :--- | :---: | :--- |
| **🚫 Avoid / Contraindicated** | **1** | **Clopidogrel (Plavix)** (CYP2C19) |
| **⬇️ Reduce Dose** | **1** | **Warfarin (Coumadin)** (VKORC1) |
| **⚠️ Use With Caution** | **9** | **Antineoplastic Agents** (ABCG2), **Apixaban** (ABCG2), **Dolutegravir** (ABCG2), **Felodipine** (ABCG2), **Iguratimod** (ABCG2), **Sorafenib** (ABCG2), **Sunitinib** (ABCG2), **Tenofovir** (ABCG2) |
| **🔍 Monitor** | **1** | **Irinotecan** (RGS5/RXRG/NR1I2/ABCG2) |
| **✅ Preferred Alternatives** | **55** | **Beta Blocking Agents, Selective** (), **Bisphosphonates** (FDPS), **Opioid Anesthetics** (ABCG2), **Other General Anesthetics** (ABCG2), **Vitamin B-Complex, Incl. Combinations** (MTHFR), **Amisulpride** (), **Atenolol** (MOV10/AGT/ADD1/GRK4/SLC25A31/ADRB2), **Atorvastatin** (PRDM16/AGT/SCAP/ABCG2/MYLIP) |

##### 4.1 Allelic Fraction (VAF) Skewing & Mosaicism / Paralog Uncertainty Audit
| Gene | Variant & Coordinate | Locus DP | Observed VAF | Classification | Technical Interpretation |
| :--- | :--- | :---: | :---: | :--- | :--- |
| **ATM** | `c.1236-2del` (`chr11:108250699`) | `18x` | **0.17** | Pathogenic/Likely pathogenic | Skewed VAF (<0.35); rule out clonal mosaicism vs. paralog alignment skew before clinical action. |
| **VDR** | `c.-1172A>G` (`chr12:47906043`) | `21x` | **0.19** | Likely pathogenic | Skewed VAF (<0.35); rule out clonal mosaicism vs. paralog alignment skew before clinical action. |
| **SLC27A3** | `p.Leu173Pro` (`chr1:153776015`) | `13x` | **0.23** | Not reviewed | Skewed VAF (<0.35); rule out clonal mosaicism vs. paralog alignment skew before clinical action. |
| **UCK2** | `c.99+808G>T` (`chr1:165828740`) | `28x` | **0.32** | Not reviewed | Skewed VAF (<0.35); rule out clonal mosaicism vs. paralog alignment skew before clinical action. |
| **SYNPR** | `c.84+40453T>G` (`chr3:63319195`) | `17x` | **0.29** | Not reviewed | Skewed VAF (<0.35); rule out clonal mosaicism vs. paralog alignment skew before clinical action. |
| **SMPD4** | `p.Pro217Leu` (`chr2:130172358`) | `21x` | **0.33** | Not reviewed | Skewed VAF (<0.35); rule out clonal mosaicism vs. paralog alignment skew before clinical action. |

### Conclusions: Diagnostic & Epistemic Decision Calculus

#### Arguments FOR Preventive Surveillance & Genotype-Guided Prescribing
1. **High-Depth Analytical Grounding:** Empirical BAM aligned coverage (**33.4x** mean depth) provides high analytical certainty (`0.98`) across SNVs and small indels.
2. **Actionable Pharmacogenomic Safety:** 12 drug-gene interactions across 41 pharmacogenes provide immediate CPIC/DPWG guidance to avoid toxicity and optimize dosing.
3. **Low-Cost Biomarker Ground-Truthing:** Routine PCP blood panels directly verify physiological homeostasis across the sample's specific prioritized pathways.

#### Arguments AGAINST Over-Intervention (Why Invasive Testing Is Unwarranted)
1. **Heterozygous Recessive Carrier & Modifier Reserve:** Heterozygous variants affecting or potentially affecting one allele in autosomal recessive or modifier genes and uni-allelic *Cis* haplotypes (7 genes) retain one intact wild-type parental copy; invasive diagnostic procedures or restrictive diets are clinically unwarranted.
2. **Statistical GWAS ≠ Monogenic Causality:** Common polygenic modifiers (AF > 1%) reflect population linkage disequilibrium proxies and must never trigger monogenic disease interventions.

### Opportunities: Physiological Ground-Truthing & Longitudinal Futures Roadmap

1. **Primary Care Preventive Blood Panel:** Incorporate the sample-specific venous blood panels and preventive evaluations from Section 2 of the Clinical Brief into the annual PCP physical.
2. **Cryptic Splice & Regulatory Functional Validation (Quadrant 2):** The **159 Cryptic AI Disruptors** exhibiting high AlphaGenome `AVI` scores driven by splicing or RNA-seq modalities can be inspected via the AlphaGenome Ref vs. Alt Track Predictions view.
3. **Automated Annual Re-Annotation & SHA-256 State Fingerprint:** Verified 0 variant reclassifications since prior snapshot (2026-10-13 08:50:53; SHA-256 c49df28612de0eff…).

### Confidence & Uncertainty Assessment
- **Analytical WGS Callset & Phasing Confidence:** **0.98** (BAM Mean Depth `33.4x`).
- **CPIC / DPWG Pharmacogenomic Prescribing Confidence:** **0.95** (41 pharmacogenes, 377 screened drugs).
- **Monogenic Carrier & Surveillance Confidence:** **0.94** (Orthogonal ClinVar, OMIM, CADD, and AlphaGenome agreement).
- **Polygenic / VUS Modifier Penetrance Confidence:** **0.70** (Requires laboratory biomarker ground-truthing).

## Appendix: Supporting Documentation & Variant Cross-Reference Directory

| Gene | Variant | Coordinates (GRCh38) | ClinVar | dbSNP | OMIM | ClinGen | AlphaGenome Atlas |
| :--- | :--- | :--- | :---: | :---: | :---: | :---: | :---: |
| **POLG** | `p.Gly737Arg` | `chr15:89323460` | [VCV13513](https://www.ncbi.nlm.nih.gov/clinvar/variation/13513/) | [rs121918054](https://www.ncbi.nlm.nih.gov/snp/rs121918054) | [MIM:203700](https://www.omim.org/entry/203700) | [POLG](https://search.clinicalgenome.org/kb/genes/POLG) | [Atlas](https://alphagenome.deepmind.com/variant/chr15:89323460) |
| **TAT** | `p.Arg57Ter` | `chr16:71576247` | [VCV402](https://www.ncbi.nlm.nih.gov/clinvar/variation/402/) | [rs118203914](https://www.ncbi.nlm.nih.gov/snp/rs118203914) | [MIM:276600](https://www.omim.org/entry/276600) | [TAT](https://search.clinicalgenome.org/kb/genes/TAT) | [Atlas](https://alphagenome.deepmind.com/variant/chr16:71576247) |
| **ATM** | `c.1236-2del` | `chr11:108250699` | [VCV574589](https://www.ncbi.nlm.nih.gov/clinvar/variation/574589/) | [rs1565381646](https://www.ncbi.nlm.nih.gov/snp/rs1565381646) | — | [ATM](https://search.clinicalgenome.org/kb/genes/ATM) | [Atlas](https://alphagenome.deepmind.com/variant/chr11:108250699) |
| **VDR** | `c.-1172A>G` | `chr12:47906043` | [VCV3336650](https://www.ncbi.nlm.nih.gov/clinvar/variation/3336650/) | [rs4516035](https://www.ncbi.nlm.nih.gov/snp/rs4516035) | — | [VDR](https://search.clinicalgenome.org/kb/genes/VDR) | [Atlas](https://alphagenome.deepmind.com/variant/chr12:47906043) |
| **MC1R** | `p.Asp294His` | `chr16:89920138` | [VCV14307](https://www.ncbi.nlm.nih.gov/clinvar/variation/14307/) | [rs1805009](https://www.ncbi.nlm.nih.gov/snp/rs1805009) | [MIM:203200](https://www.omim.org/entry/203200) | [MC1R](https://search.clinicalgenome.org/kb/genes/MC1R) | [Atlas](https://alphagenome.deepmind.com/variant/chr16:89920138) |
| **AMPD1** | `p.Glu435Gly` | `chr1:114677435` | [VCV2173226](https://www.ncbi.nlm.nih.gov/clinvar/variation/2173226/) | [rs764950035](https://www.ncbi.nlm.nih.gov/snp/rs764950035) | — | [AMPD1](https://search.clinicalgenome.org/kb/genes/AMPD1) | [Atlas](https://alphagenome.deepmind.com/variant/chr1:114677435) |
| **CTH** | `p.Thr67Ile` | `chr1:70415987` | [VCV2939](https://www.ncbi.nlm.nih.gov/clinvar/variation/2939/) | [rs28941785](https://www.ncbi.nlm.nih.gov/snp/rs28941785) | [MIM:219500](https://www.omim.org/entry/219500) | [CTH](https://search.clinicalgenome.org/kb/genes/CTH) | [Atlas](https://alphagenome.deepmind.com/variant/chr1:70415987) |
